So another test for ovarian cancer?
Sub-B2M prototype achieved 100% sensitivity and specificity. So does Bard1 anticipate this new exosome-based test to be obsolete before reaching the market?
Ann: BARD1 Collaborator Uni of QLD Announces Ovarian Cancer Data, page-12
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
61.5¢ |
Change
-0.018(2.77%) |
Mkt cap ! $67.82M | |||
| Open | High | Low | Value | Volume |
| 63.0¢ | 64.5¢ | 61.5¢ | $56.40K | 89.59K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10016 | 61.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 64.0¢ | 4900 | 1 |
View Market Depth
| Last trade - 15.16pm 02/08/2024 (20 minute delay) ? |
| IIQ (ASX) Chart |